Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Crovalimab add-on to IVIg for Guillain-Barré syndrome
2021-002968-49Phase 3Terminated
- Sponsor
- Roche
- Start
- Jun 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in Guillain-Barré syndrome (GBS) comparing Crovalimab + IVIg with Placebo + IVIg (2 arms). Primary endpoint: Proportion of participants who reach FG <=1 on GBS-DS at Week 24. Started Jun 2022; status: terminated.
02
Drugs
crovalimab
03
Conditions
Guillain-Barré syndrome (GBS)
Beyond the preview
Go deeper on 2021-002968-49.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2021-002968-49.